Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Two-part study of SBT-020 in early-stage Huntington's disease
2016-003730-25Phase 2Completed
- Sponsor
- Stealth BioTherapeutics
- Start
- Jan 2017
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of SBT-20 in Huntington disease (HD), sponsored by Stealth BioTherapeutics. Primary endpoints: Tolerability and safety, Pharmacokinetics of SBT-020 and 1 more. Started Jan 2017; status: completed.
02
Drugs
SBT-20
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2016-003730-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003730-25.